PROTECTIVE MECHANISMS WITH ATTENUATED LENTIVIRAL VACCINES

$146,579P51FY2009RRNIH

University Of California At Davis, Davis CA

Investigators

Linked publications & trials

Paper 39315417 Paper 39084478 Paper 38221724 Paper 37183431 Paper 36169578 Paper 34607967 Paper 33166366 Paper 32781858 Paper 31468643 Paper 31379520 Paper 30979867 Paper 30620103 Paper 30333177 Paper 30165920 Paper 30152539 Paper 30016006 Paper 29930544 Paper 29727590 Paper 29701840 Paper 29432794 Paper 29256819 Paper 29072793 Paper 28895116 Paper 28832918 Paper 28724488 Paper 28669601 Paper 28659785 Paper 28054806 Paper 27940463 Paper 27930651 Paper 27903730 Paper 27876552 Paper 27655885 Paper 27614199 Paper 27601620 Paper 27466971 Paper 27409810 Paper 27110280 Paper 27099627 Paper 27036917 Paper 26865706 Paper 26817979 Paper 26801956 Paper 26765769 Paper 26758818 Paper 26727334 Paper 26697375 Paper 26678372 Paper 26579566 Paper 26503764 Paper 26426528 Paper 26418313 Paper 26414797 Paper 26375708 Paper 26235811 Paper 26177107 Paper 26159774 Paper 26052245 Paper 26030432 Paper 25963897 Paper 25870391 Paper 25816799 Paper 25810480 Paper 25757574 Paper 25730759 Paper 25545987 Paper 25492684 Paper 25450860 Paper 25442006 Paper 25422529 Paper 25412505 Paper 25354040 Paper 25246513 Paper 25221489 Paper 25179309 Paper 25102373 Paper 25068032 Paper 25063800 Paper 24979664 Paper 24925206 Paper 24810278 Paper 24776993 Paper 24741104 Paper 24731100 Paper 24610016 Paper 24582107 Paper 24498008 Paper 24446897 Paper 24436199 Paper 24436198 Paper 24390922 Paper 24346252 Paper 24330573 Paper 24326227 Paper 24307581 Paper 24273680 Paper 24215442 Paper 24210022 Paper 24167570 Paper 24164332

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. HIV is a sexually transmitted disease and a vaccine capable of preventing sexual transmission of HIV should elicit mucosal immune responses in the genital tract. The objectives of this study were to determine which immune responses confer protection from intravaginal challenge with SIVmac 239.

View original record on NIH RePORTER →